H epatitis C is a common cause of chronic liver disease globally, and its global prevalence has been estimated to be over 2%. [1] [2] [3] [4] [5] India, with one-fifth of world's population, is a major contributor to this global burden. Prevalence in India has been estimated to be between [ 8 4 _ T D $ D I F F ] 0.5% and 1.5% of general population. 6 
[ 8 3 _ T D $ D I F F ]
There are several hotspots in India such as Moga district in Punjab, where prevalence as high as 21% has been recorded in some areas. Similarly, some tribal populations in India have very high prevalence. [7] [8] [9] Hepatitis C virus (HCV) is possibly one of the commonest causes of liver cirrhosis ($28%) [ 8 6 _ T D $ D I F F ] and hepatocellular carcinoma ($26%). 10 
[ 8 5 _ T D $ D I F F ]
The burden of HCV is immense in low-and middle-income countries from South Asia (which includes India), East Asia, North Africa, the Middle East, and Southeast Asia, and contributes more than 80% of the global HCV burden. 11, 12 India's 12-18 million HCV infected cases account for a major portion of global HCV due to her enormous population. When historical data from India was populated in a previously validated HCV disease burden model, it was estimated, with the current standard of care, advanced liver disease and liver-related mortality would rise further, despite decreasing prevalence. Recently a report from North India suggested that most patients with HCV infection in India present rather late in the natural history for treatment.
13 [ 8 7 
_ T D $ D I F F ]
Of the 777 patients studied, cirrhosis was the presentation in 56% and 7% had presented with hepatocellular carcinoma. Of patients who had cirrhosis (including those with HCC), 36% were Child[ 7 2 _ T D $ D I F F ] -Turcotte-Pugh (CTP) stage A; 51% were CTP stage B and 14% were CTP stage C. Since the study was done during the [ 8 8 
interferon era, the authors had lamented that they could offer treatment only to about 45% of those who were diagnosed to have HCV infection. Has the situation changed after introduction of directly acting antiviral drugs (DAAs), which permit interferon free regimens during last two years?
HCV related cirrhosis is the commonest etiology among those who are candidates for liver transplantation [ 6 6 
_ T D $ D I F F ] (LT).
14, 15 In a study published from India, 372 liver transplant recipients were analyzed and it was noted that 31% of them had hepatitis C as etiology while additional 1.6% had co-infection of hepatitis B and C. [20] [21] [22] At our center recurrence rate has been found to be about 85%. Secondly, recurrent hepatitis C after LT often follows a more sinister course. 23 
TREATMENT BEFORE TRANSPLANTATION
Historical data clearly shows that if patients achieve [ 1 0 4 _ T D $ D I F F ] sustained viral response [ 1 0 5 _ T D $ D I F F ] (SVR), they benefit. An elegant study involving five large tertiary care Hospitals in Canada and Europe, wherein 530 patients with chronic hepatitis C with advanced fibrosis/cirrhosis were treated between 1990 and 2003 and followed up to 2011 had shown interesting results. 25 There were 192 patients (36%) who achieved SVR; in time-dependent multivariate Cox regression analysis, SVR was associated with reduced risk of all-cause mortality (hazard ratio [HR], 0.26) and reduced risk of liver-related mortality or transplantation (HR, 0.06). The 10-year cumulative incidence rate of liver-related mortality or transplantation was 1.9% with SVR and 27.4% without SVR (P [ 1 0 7 _ T D $ D I F F ] 0.001). There were 7 patients with SVR and 76 without SVR who developed HCC (10-year cumulative incidence rate, 5.1% vs 21.8%; P [ 1 0 8 _ T D $ D I F F ] 0.001), and 4 patients with SVR and 111 without SVR experienced liver failure (10-year cumulative incidence rate, 2.1%, vs 29.9%; P [ 1 0 7 _ T D $ D I F F ] 0.001). They had concluded that among patients with chronic HCV infection and advanced hepatic fibrosis, sustained virological response to interferon-based treatment was associated with lower all-cause mortality. There have also been reports of SVR leading to reversal of liver cirrhosis.
26
The problem with this form of treatment was that only 36% patients had achieved SVR. All patients in this study were not decompensated, but they were in another study that showed similar results and an SVR after antiviral therapy is a positive prognostic factor. 27 Yet another more recent study showed similar results and concluded that approximate threefold reduction in all-cause mortality is seen in patients with HCV who are treated and achieve SVR compared to those without SVR.
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[ 1 0 9 _ T D $ D I F F ] Even regression of cirrhosis was demonstrated in some cases. 29 The improved SVR rates and safety profiles of all oral DAA has led to the treatment of patients with decompensated cirrhosis awaiting LT. 30 [ 1 1 0 _ T D $ D I F F ] Moreover, it has been shown that HCV RNA becomes negative after [ 6 8 _ T D $ D I F F ] 2-4 weeks of treatment, and those who are transplanted after becoming HCV RNA negative will be have very low the risk of HCV recurrence after transplantation. 31 This treatment is generally well tolerated and there is no difference in the incidence of hospitalization, sepsis and death between treated and untreated cohorts. We have, however, yet to prove that benefits noted in interferon era can be reproduced in DAA era with better results.
The treatment of hepatitis C in decompensated cirrhotic population is primarily aimed at eradicating the circulating HCV (make the patient aviremic) and expect (a) consequent stabilization or improvement in liver function; (b) reduction in portal hypertension (c) prevent sequelae such as HCC; (d) if possible, reverse decompensation and (e) avoid LT. It goes without saying that above should be achieved safely without any added risk. There are several studies that have showed that it is feasible to treat patients with cirrhosis of liver, with better results than were possible in interferon era. [33] [34] [35] [36] Many of these trials included patients awaiting LT, 31, 37 [ 1 1 2 _ T D $ D I F F ] and those with decompensated cirrhosis of liver. 31, 38, 39 There are several controlled trials with interesting acronyms such as ALLY-1, SOLAR-1, SOLAR-2, SATURN and CORAL-1, which have shown that it is now feasible to treat patients with decompensated cirrhosis (Table 1) . In addition, there have been several real world data studies which have given similar conclusions. [47] [48] [49] [50] [51] [52] [53] Earlier experience had shown that pegylated interferon (Peg-IFN) and ribavirin (RBV) based treatment regimen failed to achieve desired aims due to poor tolerability and limited efficacy in this unique patient population. Firstly, SVR rates hovered around 25% even when using a low accelerating dose Interferon regimen,
and not all patients could be offered treatment. Only those with CTP score less than 7 could be offered therapy, as patients with more severe liver disease would lead to serious adverse events such as bacterial infections, cytopenias, and worsening decompensation. The tolerability of DAA based regimens is definitely better with exception of those who have impaired renal function. 55 Most of the studies shown in Table 1 have shown good results. What is not shown in the table is that there is also an improvement in liver function and reversal of decompensation to some extent as more and more patients become aviremic. Afdhal (2015) 56 was first to show that 48 weeks' treatment with sofosbuvir (SOF) + RBV in decompensated cirrhosis patients resulted in SVR12 rate of 72% and led to significant improvement in ascites, encephalopathy, CTP, and model for end-stage liver disease (MELD) scores in the majority. Most of his patients however were those with early disease (CTP stages A and B) and there were no CTP C patients in this trial.
SOLAR-1 and SOLAR-2 trials 36,41 carried out in US and Europe, respectively have assessed the efficacy of ledipasvir (LDV) + SOF in More recent open-label ALLY-1 study 42 [ 1 1 4 _ T D $ D I F F ] also studied compensated and decompensated cirrhosis patients and reported good results in the 60 decompensated cirrhosis patients (GT-1, 2, [ 1 1 7 _ T D $ D I F F ] 3 and 4 had SVR rates: 82%, 80%, 83%, and 100%, respectively) when treated with a combination of SOF, daclatasvir (DCV) and RBV for 12 weeks. SVR12 rates were higher in patients with CTP class A or B (93%) versus class C (56%). As in most trials studying decompensated cirrhotics, the initial dose of RBV was 600 mg/ day, and this was gradually escalated up to 1000 mg/day based on creatinine clearance values, as well as the
Astral-4 43 study included 267 patients of decompensated cirrhosis with mixed GT 1-4. Overall rates of sustained virologic response were 83% among patients who received 12 weeks of SOF-velpatasvir (VLP), 94% among those who received 12 weeks of SOF-VEL + RBV, and 86% among those who received 24 weeks of SOF-VEL.
From the real world data, experience from NHS England Expanded Access Program 
Improvement in [ 1 2 8 _ T D $ D I F F ] Portal Hypertension
Evidence for the improvement of portal hypertension is not yet robust. There are two trials that have addressed this issue. First study 56 had enrolled 50 patients with baseline hepatic venous pressure gradient (HVPG) >6 mm of Hg and were treated with SOF + RBV for 48 weeks. 66% of the patients had HVPG levels more than 12 mmHg at baseline. The study showed that 24% of these patients had a fall in HVPG to the extent exceeding 20%, and in half of them the HVPG had dropped to a value of <12 Delisting from Transplant List DAA treatment can lead to improvement in decompensated HCV cirrhosis to an extent that one is delisted from transplant list but it is not clear if he can improve to an extent that he may not need transplantation at all. Data on delisting from the LT list are scarce but accumulating. 62 Initial report was from France that described a patient with MELD score 16, refractory ascites, encephalopathy who was listed for transplantation in October 2013. Patient was treated with SOF + RBV in December 2013 and was given for 24 weeks. Follow-up till September 2014 showed that her MELD score had dropped to 12 and she was delisted from transplantation. In another subsequent study Thirteen patients in the SOLAR-1 trial 36 (6 in the pre-LT cohort) and 17 in SOLAR-2 41 (5 in pre-LT cohort) died, primarily due to worsening of hepatic decompensation, sepsis, and multi-organ dysfunction syndrome (MODS). In addition, the SOLAR-1 and 2 trials, the most common grade 3/4 adverse effects seen in the decompensated patients were an increase in serum bilirubin and a decrease in lymphocyte count. In the SOLAR-1 trial, anemia was noted in 39% who dropped their hemoglobin values to less than 10 g/ dl; in 13%, it dropped to below 8.5 g[ 1 3 7 _ T D $ D I F F ] /dl. Blood transfusion or erythropoietin was used in 15% of the cases in this trial.
In the NHS EAP study, 48 [ 1 3 7 _ T D $ D I F F ] 6% of the patients discontinued treatment due to adverse effects, while seven patients died. Adverse outcomes were more common in patients with a higher baseline MELD score, low serum albumin (<3.5 g[ 1 3 7 _ T D $ D I F F ] /dl), higher age (>65 years), and low serum sodium values (<135 mEq/L). In fact it was suggested that patient with age above 65 years and/or serum albumin values less than 3.5 g/dl one may expect more harm than benefit. In this study, [ 
3 8 _ T D $ D I F F ] anemia with hemoglobin value of <8 g[ 3 7 _ T D $ D I F F ]
/dl was seen in 5% of the cases. Acute kidney injury, (defined by an increase in serum creatinine by 1.5 times from baseline value) was seen in 3% cases. Two cases of significant hepatotoxicity related to treatment with SOF and NS5A inhibitors as part of the English early access program were recently reported. 66 Even in ASTRAL-4 cohort 43 serious adverse events occurred in 19% of patients who received 12 weeks of SOF + VLP, 16% of those who received 12 weeks of SOF + VLP plus RBV, and 18% of those who received 24 weeks of SOF + VLP. The most common adverse events were fatigue (29%), nausea (23%), and headache (22%) in all patients and anemia (31%) in the patients receiving RBV. In addition to these adverse effects, there are also reports of DAA induced hepatotoxicity. According to the core safety information for SOF, LDV and DCV no dose adjustment is required in those with hepatic impairment (irrespective of CTP score). 67, 68 However, few patients with decompensated cirrhosis have had treatment with DAAs, so the exact pharmacokinetics in this population have not been characterized.
Hepatocellular [ 1 4 0 _ T D $ D I F F ] Carcinoma (HCC)
There have been increasing reports of development of HCC after viral clearance with DAA. 
TREATMENT AFTER LIVER TRANSPLANTATION
Recurrent HCV infection is common after LT for HCV related cirrhosis and may be seen in over 80% such cases. It is also a recognized cause of mortality in these patients. 79 Achievement of SVR with treatment could improve outcome significantly in these patients, 80 [ 1 4 9 _ T D $ D I F F ] but use of interferon containing regimens was associated with significant morbidity. 81 Therefore it was considered a difficult to treat group a few years back. Availability of DAAs has changed all that. Many of these drugs can now be safely given concomitantly with immunosuppressive agents (see Table 2 Thus, it is now possible to treat these patients in postliver-transplant period. 41, 42, 83 Successful therapy has been shown to have a positive impact on both graft and patient survival. 81 Newer The predominant circulating metabolite, GS-331007, is formed by dephosphorylation of nucleotide metabolites, and accounts for approximately 78% of total systemic exposure and is principally excreted in urine. 68 RBV has extensive volume of distribution and is eliminated mainly through the kidneys. 91 With currently used DAAs such as SOF, LDV and DCV, there is no need to adjust the dose of tacrolimus (TAC) or cyclosporine A (CSA) when given simultaneously. 88, 92 However, same rule does not apply to all DAAs. SMV when given along with calcineurin inhibitors does not significantly affect the levels of the latter, but results in a rise in plasma concentrations of SMV (approximately 200%) with TAC and 600% with CSA), therefore this combination is not recommended. 90 When GRZ/EBV are used with TAC, the combination leads to approximately 40% increase in TAC levels, necessitating frequent monitoring of TAC levels. When used along with CSA, GRZ/EBV levels may rise up to 15 times and hence this combination is also not recommended to be used. 93 Wherever rt boost is required in DAA regimens, the dose of calcineurin inhibitors will need to be adjusted as per levels, as [ 1 6 2 _ T D $ D I F F ] rt is a strong CYP3A inhibitor.
Safety and Efficacy
There is ample data now to show that newer DAAs are safe as well as effective when used after liver showed that SOF + RBV combination therapy for 24 weeks is an effective and well-tolerated interferon-free regimen for post-transplantation HCV infection. In their study of 40 post-livertransplant HCV infected patients, SVR was found to be 70%. A few other studies have also shown the beneficial effect of this regimen in post-liver-transplant patients. 81, 94 CORAL-1 trial studied OMB/PTV + DSB in post-transplant recurrent HCV (GT-1) infection and showed 97% SVR rates.
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[ 1 6 4 _ T D $ D I F F ] Another UCLA study using SOF + SMV also showed 93% SVR rates in patients treated for recurrent HCV infection after liver transplantation and confirmed the efficacy of DAAs in this setting. 95 Safety as well as efficacy of DAA was also clearly demonstrated in the post-liver-transplant limb of SOLAR trials. 36, 41 Predominantly GT-1 patients were treated with SOF + LDV + RBV In the SOLAR-1 study, for 12 or 24 weeks. SVR12 was achieved in 95% patients with F0-3 fibrosis and 98% with CTP stage-A cirrhosis. FCH is an uncommon complication of post-[ 1 6 6 _ T D $ D I F F ] liver-transplant HCV recurrence and may lead to death if untreated. SOLAR-1 (6 cases) and SOLAR-2 trials (5 cases), showed that FCH patients can also be successfully treated as well as any other HCV patients. These studies also did not record any drugto-drug interaction with any of the immunosuppressive agents in these trial.
A study by In recent open-label ALLY-1 study, 42 53 liver transplant recipients with recurrent HCV infection were treated with a combination of DCV + SOF + RBV. SVR12 was achieved in 50 out of 53 patients (94%). Even though CSA can increase DCV exposure with a 40% increase in AUC0-24, this is not of much clinical consequence. Thus, the standard immunosuppression need not be changed when co-administered with DAAs. CORAL-1 trial results also confirm these findings.
Pre-Emptive or Reactive Treatment?
Now that DAAs have been found to be safe and effective for treatment of post-liver-transplant HCV recurrence, one question still remains unanswered. Should such patients be treated pre-emptively, 97, 98 [ 1 Main argument for reactive treatment would be to avoid unnecessary drugs at a time when patient is recovering from a major surgery. Currently most hepatologists wait for about three months before checking HCV-RNA levels in patients who are doing well. This allows initial upheavals of transplant surgery to [ 1 7 4 _ T D $ D I F F ] stabilize and also allows time for steroid dose to be brought down. Once a diagnosis of recurrence has been made, treatment can safely be instituted. The fact remains that patients with high viral load, GT 1 infection, females, older donor age, being treated for cytomegalovirus or for acute rejection, have a high risk for rapidly progressive recurrent hepatitis C. 99 Therefore it must be accepted that the most appropriate time for starting DAA treatment in post-transplant period has not yet been settled and additional innovative approaches may help us in arriving at such decision.
For example one report 100 has described the role of the expression of HLA variants and the interleukin 28B (IL28B) C/C GT (rs12979860) in the prediction of the outcome of [ 1 7 6 _ T D $ D I F F ] LT in HCV-recipients after studying 449 patients with a median follow-up of 10 years. They showed that the graft survival in HLA-DRB1*11-positive recipients was significantly longer. Graft survival was much better if IL28B [ 1 7 7 _ T D $ D I F F ] GT of both recipient and donor was C/C. On basis of this information, one may suggest that patients lacking both these markers should undergo antiviral therapy as soon as possible after transplantation whereas others probably can wait until their clinical course has completely stabilized and recurrence has been detected. 101 In the latter situation it may prevent emotional dilemmas as described elsewhere.
102
But there is a flip side too. Firstly, one must consider a definite risk of worsening of liver disease on DAA's as has been outlined above. Deaths have been recorded due to worsening liver decompensation in all the trials. Such worsening becomes more probable at higher MELD score. Secondly, SVR may preclude the patient from receiving anti-HCV-positive graft in DDLT setting and delay his chances of getting early transplantation. Thirdly, improvement in MELD may temporarily eliminate the opportunity to have curative treatment, i.e. LT. One may improve decompensation to some extent and be delisted from transplantation waiting list and thereby be condemned to live a poor quality of life. Such a patient may be placed in a situation where one's productivity or creativity is seriously hampered due to poor quality of health repeated 103,104 However, it must be understood that factors that determine improvement after DAA treatment in decompensated cirrhosis have not been fully elucidated. Analysis of data from European Liver and Intestine Association Study 63 suggests that patient with MELD scores less than 16 had high chance (25/51; 49.%) of improving and being delisted from liver transplant list. On an average MELD score less than 16, as per historical data, has a 12-week mortality less than 2%. 99 Therefore, this group of patients are ideal for being offered DAA treatment prior to transplantation. In the same study, it has been shown that patients who had MELD scores over 20, had much lower (2/13; 15.4%) chance of being delisted from transplant list and 12-week mortality in this group of patients as per historical data may be over 10-19% . Thus this is a group where chances of being harmed are more than being . This is the group where the pros and cons need to be discussed with the patient and family and decision made regarding DAA treatment of transplantation. It may be recalled that even in other studies mentioned above, 31, 59 improvement is mainly seen among those who have MELD score 15 or less and hardly anyone with MELD score >20 has shown significant improvement. This may signify a point of no return for liver decompensation as far as therapy for HCV is concerned and they will be better off receiving LT first and being treated later, rather than accept the risk of further worsening or that of HCC recurrence. 
CONCLUSIONS
Several currently available DAA regimens for patients with decompensated cirrhosis are associated with high SVR rates and some patients with MELD scores lower than 16 may even be delisted from transplant rosters. They are also safe in majority of patients with MELD scores less than 20. At the same time, SVR rates of patients treated for early HCV recurrence after [ 1 9 0 _ T D $ D I F F ] LT has also been impressive. It should also be understood that even with successful therapy for HCV in cirrhosis, the risk of progressive liver disease and hepatocellular carcinoma is not eliminated. SVR may prevent a patient from being eligible for anti-[ 1 9 1 _ T D $ D I F F ] HCV-positive organs and delisting may preclude the patient from a curative treatment which can lead to good quality of life. While the medical science is working hard to identify predictors of good outcome in decompensated cirrhosis patients, the best approach at present appears to be to individualize treatment strategy in a given patient to suit his requirement, both medical and social. As a thumb rule, those MELD scores >20 should be advised to be treated after [
9 4 _ T D $ D I F F ] CONFLICTS OF INTEREST
The author has none to declare.
